Establishment and characterization of an ovarian yolk sac tumor patient-derived xenograft model
link.springer.com shows its articles on its own site.
Read the article on link.springer.com ↗Article · May 2021 · 1 min read
In brief
In brief
Researchers established the first patient-derived xenograft model of ovarian yolk sac tumor by implanting patient tissue into immunocompromised mice. The model faithfully replicated the original tumor's histology and immunohistochemistry, and responded to BEP chemotherapy similarly to clinical outcomes, providing a valuable platform for testing new treatments and studying disease mechanisms.
Written by the GCMD Library team from the article.
Abstract
Objective
The lack of appropriate preclinical models of ovarian yolk sac tumor (OYST) is currently hindering the pursuit of new methods of treatment and investigation of the pathogenesis of the disease. We developed and characterized an OYST patient-derived xenograft (PDX) model in this study.
Methods
Tumor fragments from a patient with an OYST were implanted subcutaneously into BALB/c Nude mice. Engrafted xenografts were compared with the original tumor according to histology, immunohistochemistry, humanized identified, and drug efficacy testing with in vivo treatment programs.
Results
There was a high degree of histologic and immunohistochemical (IHC) resemblance between the established PDX model and its corresponding human tumors. Bleomycin, etoposide, and cisplatin (JEB) chemotherapy regimens were effective in clinical patients and were effective in the OYST PDX model; therefore, the effect of PDX intervention was consistent with clinical outcomes of OYSTs.
Conclusion
We have successfully established an OYST PDX model. This OYST model preserves the basic molecular features of the primary human tumor, thereby providing a valuable method to preclinically evaluate new treatments and explore disease pathogenesis.